Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE).

Enomoto T, Aoki D, Hattori K, Jinushi M, Kigawa J, Takeshima N, Tsuda H, Watanabe Y, Yoshihara K, Sugiyama T.

Int J Gynecol Cancer. 2019 Jul;29(6):1043-1049. doi: 10.1136/ijgc-2019-000384.

PMID:
31263023
2.

A phase II randomized controlled study of pegylated liposomal doxorubicin and carboplatin vs. gemcitabine and carboplatin for platinum-sensitive recurrent ovarian cancer (GOTIC003/intergroup study).

Fujiwara H, Ushijima K, Nagao S, Takei Y, Shimada M, Takano M, Yoshino K, Kawano Y, Hirashima Y, Nagase S, Nishio S, Nishikawa T, Ito K, Shoji T, Kimura E, Takano T, Sugiyama T, Kigawa J, Fujiwara K, Suzuki M.

Int J Clin Oncol. 2019 Oct;24(10):1284-1291. doi: 10.1007/s10147-019-01471-5. Epub 2019 May 24.

PMID:
31127479
3.

Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival.

Matsuo K, Shimada M, Yamaguchi S, Kigawa J, Tokunaga H, Tabata T, Kodama J, Kawana K, Mikami M, Sugiyama T.

J Clin Med. 2019 Jan 30;8(2). pii: E156. doi: 10.3390/jcm8020156.

5.

Impact of institutional accreditation by the Japan Society of Gynecologic Oncology on the treatment and survival of women with cervical cancer.

Mikami M, Shida M, Shibata T, Katabuchi H, Kigawa J, Aoki D, Yaegashi N.

J Gynecol Oncol. 2018 Mar;29(2):e23. doi: 10.3802/jgo.2018.29.e23. Epub 2017 Dec 27.

6.

Chemoresistance of Gastric-Type Mucinous Carcinoma of the Uterine Cervix: A Study of the Sankai Gynecology Study Group.

Kojima A, Shimada M, Mikami Y, Nagao S, Takeshima N, Sugiyama T, Teramoto N, Kiyokawa T, Kigawa J, Nishimura R; Sankai Gynecology Study Group.

Int J Gynecol Cancer. 2018 Jan;28(1):99-106. doi: 10.1097/IGC.0000000000001145.

PMID:
29206664
7.

Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.

Itamochi H, Oishi T, Oumi N, Takeuchi S, Yoshihara K, Mikami M, Yaegashi N, Terao Y, Takehara K, Ushijima K, Watari H, Aoki D, Kimura T, Nakamura T, Yokoyama Y, Kigawa J, Sugiyama T.

Br J Cancer. 2017 Aug 22;117(5):717-724. doi: 10.1038/bjc.2017.228. Epub 2017 Jul 20.

8.

Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study.

Tanioka M, Yamaguchi S, Shimada M, Nagao S, Takehara K, Nishimura M, Morita S, Negoro S, Fujiwara K, Kigawa J.

Med Oncol. 2017 Aug;34(8):134. doi: 10.1007/s12032-017-0992-4. Epub 2017 Jul 5.

PMID:
28681218
9.

Neoadjuvant chemotherapy with docetaxel and carboplatin followed by radical hysterectomy for stage IB2, IIA2, and IIB patients with non-squamous cell carcinoma of the uterine cervix.

Shimada M, Nagao S, Fujiwara K, Takeshima N, Takizawa K, Shoji T, Sugiyama T, Yamaguchi S, Nishimura R, Kigawa J.

Int J Clin Oncol. 2016 Dec;21(6):1128-1135. Epub 2016 Jul 5.

PMID:
27380169
10.

Feasibility study on combination chemotherapy using nogitecan hydrochloride (topotecan) and cisplatin for patients with metastatic, persistent, or recurrent uterine cervical cancer.

Shimada M, Sato S, Oishi T, Itamochi H, Kigawa J, Takeshima N, Aoki D, Aoki Y, Nambu Y, Ochiai K.

Int J Clin Oncol. 2016 Oct;21(5):969-974. Epub 2016 May 3.

PMID:
27142771
11.

Feasibility Study of Adjuvant Chemotherapy Using Taxane Plus Carboplatin for High-Risk Patients With Uterine Cervical Non-Squamous Cell Carcinoma After Radical Hysterectomy.

Sato S, Shimada M, Ohta T, Kojimahara T, Tokunaga H, Takano T, Yamaguchi S, Tanabe H, Nishio S, Kigawa J.

Int J Gynecol Cancer. 2016 Mar;26(3):561-7. doi: 10.1097/IGC.0000000000000650.

PMID:
26825829
12.

Human papillomavirus type-specific persistence and reappearance after successful conization in patients with cervical intraepithelial neoplasia.

Kudoh A, Sato S, Itamochi H, Komatsu H, Nonaka M, Sato S, Chikumi J, Shimada M, Oishi T, Kigawa J, Harada T.

Int J Clin Oncol. 2016 Jun;21(3):580-7. doi: 10.1007/s10147-015-0929-x. Epub 2015 Nov 27.

PMID:
26614089
13.

What is an appropriate second-line regimen for recurrent endometrial cancer? Ancillary analysis of the SGSG012/GOTIC004/Intergroup study.

Nagao S, Nishio S, Okada S, Otsuki T, Fujiwara K, Tanabe H, Takano M, Hasumi Y, Takei Y, Hasegawa T, Matsumoto T, Fujiwara K, Takekuma M, Nakamura K, Shimada M, Suzuki M, Kigawa J.

Cancer Chemother Pharmacol. 2015 Aug;76(2):335-42. doi: 10.1007/s00280-015-2793-9. Epub 2015 Jun 20.

PMID:
26092322
14.

Fibroblast growth factor receptor 2 is associated with poor overall survival in clear cell carcinoma of the ovary and may be a novel therapeutic approach.

Itamochi H, Oumi N, Oishi T, Taniguchi F, Shoji T, Fujiwara H, Sugiyama T, Suzuki M, Kigawa J, Harada T.

Int J Gynecol Cancer. 2015 May;25(4):570-6. doi: 10.1097/IGC.0000000000000414.

PMID:
25756405
15.

Loss of ARID1A expression is associated with poor prognosis in patients with stage I/II clear cell carcinoma of the ovary.

Itamochi H, Oumi N, Oishi T, Shoji T, Fujiwara H, Sugiyama T, Suzuki M, Kigawa J, Harada T.

Int J Clin Oncol. 2015 Oct;20(5):967-73. doi: 10.1007/s10147-015-0811-x. Epub 2015 Mar 6.

PMID:
25744580
16.

Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma.

Okamoto A, Sehouli J, Yanaihara N, Hirata Y, Braicu I, Kim BG, Takakura S, Saito M, Yanagida S, Takenaka M, Yamaguchi N, Morikawa A, Tanabe H, Yamada K, Yoshihara K, Enomoto T, Itamochi H, Kigawa J, Matsumura N, Konishi I, Aida S, Aoki Y, Ishii N, Ochiai K, Akiyama T, Urashima M.

PLoS One. 2015 Feb 6;10(2):e0116977. doi: 10.1371/journal.pone.0116977. eCollection 2015.

17.

Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma.

Miyata K, Yotsumoto F, Nam SO, Odawara T, Manabe S, Ishikawa T, Itamochi H, Kigawa J, Takada S, Asahara H, Kuroki M, Miyamoto S.

Cancer Med. 2014 Oct;3(5):1159-69. doi: 10.1002/cam4.301. Epub 2014 Jul 24.

18.

Incidence and risk factors for lower limb lymphedema after gynecologic cancer surgery with initiation of periodic complex decongestive physiotherapy.

Deura I, Shimada M, Hirashita K, Sugimura M, Sato S, Sato S, Oishi T, Itamochi H, Harada T, Kigawa J.

Int J Clin Oncol. 2015 Jun;20(3):556-60. doi: 10.1007/s10147-014-0724-0. Epub 2014 Jul 4.

PMID:
24993674
19.

The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.

Oishi T, Itamochi H, Kudoh A, Nonaka M, Kato M, Nishimura M, Oumi N, Sato S, Naniwa J, Sato S, Shimada M, Kigawa J, Harada T.

Oncol Rep. 2014 Aug;32(2):553-8. doi: 10.3892/or.2014.3268. Epub 2014 Jun 13.

PMID:
24927217
20.

Apparent diffusion coefficient (ADC) measurement in endometrial carcinoma: effect of region of interest methods on ADC values.

Inoue C, Fujii S, Kaneda S, Fukunaga T, Kaminou T, Kigawa J, Harada T, Ogawa T.

J Magn Reson Imaging. 2014 Jul;40(1):157-61. doi: 10.1002/jmri.24372. Epub 2013 Oct 31.

PMID:
24677497
21.

Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy following radical surgery: SGSG/TGCU Intergroup Surveillance.

Shimada M, Nishimura R, Nogawa T, Hatae M, Takehara K, Yamada H, Kurachi H, Yokoyama Y, Sugiyama T, Kigawa J.

Mol Clin Oncol. 2013 Jul;1(4):780-784. Epub 2013 May 9.

22.

Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary.

Kudoh A, Oishi T, Itamochi H, Sato S, Naniwa J, Sato S, Shimada M, Kigawa J, Harada T.

Int J Gynecol Cancer. 2014 Mar;24(3):444-53. doi: 10.1097/IGC.0000000000000091.

PMID:
24552895
23.

Comparison of adjuvant chemotherapy and radiotherapy in patients with cervical adenocarcinoma of the uterus after radical hysterectomy: SGSG/TGCU Intergroup surveillance.

Shimada M, Nishimura R, Hatae M, Hiura M, Takehara K, Tase T, Yamada H, Kurachis H, Sugiyama T, Kigawa J.

Eur J Gynaecol Oncol. 2013;34(5):425-8.

PMID:
24475576
24.

Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study.

Takano T, Otsuki T, Tokunaga H, Toyoshima M, Utsunomiya H, Nagase S, Niikura H, Ito K, Yaegashi N, Yamada H, Tase T, Kagabu M, Shoji T, Sugiyama T, Sato N, Fujimoto T, Terada Y, Nakahara K, Kurachi H, Yokoyama Y, Mizunuma H, Soeda S, Nishiyama H, Matsumoto T, Sato S, Shimada M, Kigawa J.

Int J Clin Oncol. 2014 Dec;19(6):1052-8. doi: 10.1007/s10147-013-0658-y. Epub 2014 Jan 7.

PMID:
24395448
25.

Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary.

Itamochi H, Nishimura M, Oumi N, Kato M, Oishi T, Shimada M, Sato S, Naniwa J, Sato S, Kudoh A, Kigawa J, Harada T.

Int J Gynecol Cancer. 2014 Jan;24(1):61-9. doi: 10.1097/IGC.0000000000000014.

PMID:
24362713
26.

Correlation of apparent diffusion coefficient value with prognostic parameters of endometrioid carcinoma.

Inoue C, Fujii S, Kaneda S, Fukunaga T, Kaminou T, Kigawa J, Harada T, Ogawa T.

J Magn Reson Imaging. 2015 Jan;41(1):213-9. doi: 10.1002/jmri.24534. Epub 2013 Dec 12.

PMID:
24339027
27.

Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study.

Nagao S, Nishio S, Michimae H, Tanabe H, Okada S, Otsuki T, Tanioka M, Fujiwara K, Suzuki M, Kigawa J.

Gynecol Oncol. 2013 Dec;131(3):567-73. doi: 10.1016/j.ygyno.2013.09.021. Epub 2013 Sep 25.

PMID:
24076450
28.

New strategy for overcoming resistance to chemotherapy of ovarian cancer.

Kigawa J.

Yonago Acta Med. 2013 Jun;56(2):43-50. Epub 2013 Jul 12. Review.

29.

Nedaplatin: a cisplatin derivative in cancer chemotherapy.

Shimada M, Itamochi H, Kigawa J.

Cancer Manag Res. 2013 May 8;5:67-76. doi: 10.2147/CMAR.S35785. Print 2013.

30.

Outcome of stage IB2-IIB patients with bulky uterine cervical cancer who underwent neoadjuvant chemotherapy followed by radical hysterectomy.

Uegaki K, Shimada M, Sato S, Deura I, Naniwa J, Sato S, Oishi T, Itamochi H, Harada T, Kigawa J.

Int J Clin Oncol. 2014 Apr;19(2):348-53. doi: 10.1007/s10147-013-0559-0. Epub 2013 Apr 17.

PMID:
23592280
31.

Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene.

Itamochi H, Kato M, Nishimura M, Oumi N, Oishi T, Shimada M, Sato S, Naniwa J, Sato S, Nonaka M, Kudoh A, Terakawa N, Kigawa J, Harada T.

Hum Cell. 2013 Sep;26(3):121-7. doi: 10.1007/s13577-013-0062-y. Epub 2013 Feb 21.

PMID:
23430509
32.

Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2.

Itamochi H, Kato M, Nishimura M, Oishi T, Shimada M, Sato S, Naniwa J, Sato S, Nonaka M, Kudoh A, Terakawa N, Kigawa J, Harada T.

Hum Cell. 2012 Dec;25(4):111-5. doi: 10.1007/s13577-012-0048-1. Epub 2012 Dec 30.

PMID:
23274876
33.

[Molecular targeted therapies for epithelial ovarian cancer].

Itamochi H, Kigawa J.

Nihon Rinsho. 2012 Jun;70 Suppl 4:622-7. Japanese. No abstract available.

PMID:
23156321
34.

[Surgical treatment and function preservation in cervical cancer].

Deura I, Shimada M, Kigawa J.

Nihon Rinsho. 2012 Jun;70 Suppl 4:213-6. Japanese. No abstract available.

PMID:
23156245
35.

Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group.

Oshita T, Itamochi H, Nishimura R, Numa F, Takehara K, Hiura M, Tanimoto H, Noma J, Hayase R, Murakami A, Fujimoto H, Kanamori Y, Kitada F, Shitsukawa K, Nagaji M, Minagawa Y, Fujiwara M, Kigawa J.

Int J Clin Oncol. 2013 Dec;18(6):1107-13. doi: 10.1007/s10147-012-0483-8. Epub 2012 Oct 17.

PMID:
23073623
36.

Regulation of autophagy and its associated cell death by "sphingolipid rheostat": reciprocal role of ceramide and sphingosine 1-phosphate in the mammalian target of rapamycin pathway.

Taniguchi M, Kitatani K, Kondo T, Hashimoto-Nishimura M, Asano S, Hayashi A, Mitsutake S, Igarashi Y, Umehara H, Takeya H, Kigawa J, Okazaki T.

J Biol Chem. 2012 Nov 16;287(47):39898-910. doi: 10.1074/jbc.M112.416552. Epub 2012 Oct 3.

37.

Objective evaluation of the alleviating effects of Goshajinkigan on peripheral neuropathy induced by paclitaxel/carboplatin therapy: A multicenter collaborative study.

Kaku H, Kumagai S, Onoue H, Takada A, Shoji T, Miura F, Yoshizaki A, Sato S, Kigawa J, Arai T, Tsunoda S, Tominaga E, Aoki D, Sugiyama T.

Exp Ther Med. 2012 Jan;3(1):60-65. Epub 2011 Oct 24.

38.

Clinical trials and future potential of targeted therapy for ovarian cancer.

Itamochi H, Kigawa J.

Int J Clin Oncol. 2012 Oct;17(5):430-40. doi: 10.1007/s10147-012-0459-8. Epub 2012 Aug 28. Review.

PMID:
22926640
39.

Molecular-targeted therapies for ovarian cancer.

Kigawa J.

Int J Clin Oncol. 2012 Oct;17(5):423. doi: 10.1007/s10147-012-0456-y. Epub 2012 Aug 28. No abstract available.

PMID:
22926639
40.

Regulation of cell migration by sphingomyelin synthases: sphingomyelin in lipid rafts decreases responsiveness to signaling by the CXCL12/CXCR4 pathway.

Asano S, Kitatani K, Taniguchi M, Hashimoto M, Zama K, Mitsutake S, Igarashi Y, Takeya H, Kigawa J, Hayashi A, Umehara H, Okazaki T.

Mol Cell Biol. 2012 Aug;32(16):3242-52. doi: 10.1128/MCB.00121-12. Epub 2012 Jun 11.

41.

Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells.

Nonaka M, Itamochi H, Kawaguchi W, Kudoh A, Sato S, Uegaki K, Naniwa J, Sato S, Shimada M, Oishi T, Terakawa N, Kigawa J, Harada T.

Int J Gynecol Cancer. 2012 Jul;22(6):922-9. doi: 10.1097/IGC.0b013e31824f0b13.

PMID:
22672985
42.

Area under the curve calculation of nedaplatin dose used in combination chemotherapy with irinotecan in a phase I study of gynecologic malignancies.

Shimada M, Fujiwara H, Sato S, Oishi T, Itamochi H, Machida S, Takei Y, Harada T, Suzuki M, Kigawa J.

Cancer Chemother Pharmacol. 2012 Jul;70(1):33-8. doi: 10.1007/s00280-012-1885-z. Epub 2012 May 18.

PMID:
22610355
43.

Feasibility study on biweekly paclitaxel treatment as maintenance chemotherapy in advanced müllerian carcinoma.

Minagawa Y, Shimada M, Itamochi H, Sato S, Sato S, Okada M, Kitada F, Kigawa J.

Gynecol Obstet Invest. 2012;73(4):272-6. doi: 10.1159/000332368. Epub 2012 Mar 1.

PMID:
22378216
44.

Histological grading of ovarian clear cell adenocarcinoma: proposal for a simple and reproducible grouping system based on tumor growth architecture.

Yamamoto S, Tsuda H, Shimazaki H, Takano M, Yoshikawa T, Kuzuya K, Tsuda H, Kurachi H, Kigawa J, Kikuchi Y, Sugiyama T, Matsubara O.

Int J Gynecol Pathol. 2012 Mar;31(2):116-24. doi: 10.1097/PGP.0b013e3182285c90.

PMID:
22317866
45.

MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.

Bartholomeusz C, Oishi T, Saso H, Akar U, Liu P, Kondo K, Kazansky A, Krishnamurthy S, Lee J, Esteva FJ, Kigawa J, Ueno NT.

Mol Cancer Ther. 2012 Feb;11(2):360-9. doi: 10.1158/1535-7163.MCT-11-0400. Epub 2011 Dec 5.

46.
47.

Evaluation of a formula for individual dosage of nedaplatin based on renal function.

Sato S, Fujiwara H, Oishi T, Shimada M, Machida S, Takei Y, Itamochi H, Suzuki M, Kigawa J.

Cancer Chemother Pharmacol. 2012 Mar;69(3):599-603. doi: 10.1007/s00280-011-1739-0. Epub 2011 Sep 15.

PMID:
21918903
48.

Clear cell adenocarcinoma with a component of poorly differentiated histology: a poor prognostic subgroup of ovarian clear cell adenocarcinoma.

Yamamoto S, Tsuda H, Shimazaki H, Takano M, Yoshikawa T, Kuzuya K, Tsuda H, Kurachi H, Kigawa J, Kikuchi Y, Sugiyama T, Matsubara O.

Int J Gynecol Pathol. 2011 Sep;30(5):431-41. doi: 10.1097/PGP.0b013e3182165eba.

PMID:
21804390
49.

Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27.

Itamochi H, Yoshida T, Walker CL, Bartholomeusz C, Aoki D, Ishihara H, Suzuki N, Kigawa J, Terakawa N, Ueno NT.

Gynecol Oncol. 2011 Sep;122(3):641-7. doi: 10.1016/j.ygyno.2011.05.003. Epub 2011 Jun 8.

PMID:
21652059
50.

Inhibiting the mTOR pathway synergistically enhances cytotoxicity in ovarian cancer cells induced by etoposide through upregulation of c-Jun.

Itamochi H, Oishi T, Shimada M, Sato S, Uegaki K, Naniwa J, Sato S, Nonaka M, Terakawa N, Kigawa J, Harada T.

Clin Cancer Res. 2011 Jul 15;17(14):4742-50. doi: 10.1158/1078-0432.CCR-11-0190. Epub 2011 May 24.

Supplemental Content

Loading ...
Support Center